Anxiety and depressive disorders in Parkinson’s disease

Akhmadeeva G.N.; Magzhanov R.V.; Tayupova G.N.; Bajtimerov A.R.; Hidijatova I.M.

doi:https://doi.org/10.17116/jnevro20171171254-58

Close metadata

Recommended articles:

Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10

Influence of enzymatic activity of microbiota on hemodynamics, arterial stiffness and emotional state of patients with mild-to-moderate risk of cardiovascular complications. Russian Cardiology Bulletin. 2024;(4-2):128-136

Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16

Pathogenetic interrelations of hypogonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83

The experience of diagnosing Alzheimer’s disease based on the study of cerebrospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97

Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27

A personalized approach to the treatment of chronic tension headache and comorbid mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):51-57

Experience with the use of amitriptyline for chronic pelvic pain associated with endometriosis. Russian Journal of Human Reproduction. 2025;(1):86-93

Cognitive functions assessment of elderly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50

Abstract:

This review presents the most recent data of worldwide research on anxiety and depressive disorders in patients with Parkinson’s disease. Their characteristics and epidemiology, pathogenetic and clinical features, methods of diagnosis and treatment are presented. Depression occurs in 40—50% of patients with PD, anxiety in 17—43% of patients. Pramipexole, a dopamine agonist, is only one drug recommended for depression treatment. Nortriptyline and desipramine, belonging to the group of tricyclic antidepressants (TCAs), are considered to be possibly effective. There are no clear recommendations for treatment of anxiety. In general, methods of therapy of anxiety and depressive disorders in PD are not well understood which determines the conduct of large-scale studies in the future.

Keywords:

Parkinson’s disease

cognitive disorders

dementia

anxiety

depression

Authors:

Akhmadeeva G.N.

Kuvatova Rebublic Clinical Hospital, Ufa, Russia;
Rebublic Consultative Diagnostic Centre of the Extrapyramidal Pathology and the botulinotherapy, Ufa, Russia;
Institute of Biochemistry and Genetics of Ufa Science Centre, Ufa, Russia

Magzhanov R.V.

Bashkir State Medical University

SPIN RSCI: 8300-6185
Scopus AuthorID: 6603567015
ORCID: 0000-0003-1246-4833

Tayupova G.N.

Kuvatova Republican Clinical Hospital, Ufa, Russia

Bajtimerov A.R.

RB City Hospital №21, Ufa, Russia

Hidijatova I.M.

Institute of Biochemistry and Genetics of Ufa Science Centre, Ufa, Russia

Close metadata

References:

Antonini A, Barone P, Marconi R, Morgante L, Zappulla S, Pontieri FE, Ramat S, Ceravolo MG, Meco G, Cicarelli G, Pederzoli M, Manfredi M, Ceravolo R, Mucchiut M, Volpe G, Abbruzzese G, Bottacchi E, Bartolomei L, Ciacci G, Cannas A, Randisi MG, Petrone A, Baratti M, Toni V, Cossu G, Del Dotto P, Bentivoglio AR, Abrignani M, Scala R, Pennisi F, Quatrale R, Gaglio RM, Nicoletti A, Perini M, Avarello T, Pisani A, Scaglioni A, Martinelli PE, Iemolo F, Ferigo L, Simone P, Soliveri P, Troianiello B, Consoli D, Mauro A, Lopiano L, Nastasi G, Colosimo C. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol. 2012;259(12):2621-31. doi:10.1007/s00415-012-6557-8
Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G, Robinson RG. A validation study of depressive syndromes in Parkinson’s disease. Mov Disord. 2008;23(4):538-546. doi:10.1002/mds.21866
Tumas V, Rodrigues GG, Farias TL, Crippa JA. The accuracy of diagnosis of major depression in patients with Parkinson’s disease: a comparative study among the UPDRS, the geriatric depression scale and the Beck depression inventory. Arq Neuropsiquiatr. 2008;66(2A):152-156. doi:10.1590/s0004-282x2008000200002
Oguru M, Tachibana H, Toda K, Okuda B, Oka N. Apathy and depression in Parkinson disease. J Geriatr Psych Neurology. 2010;23(1):35-41. doi:10.1177/0891988709351834
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183-189. doi:10.1002/mds.21803
Leentjens AF, Marinus J, Van Hilten JJ, Lousberg R, Verhey FR. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci. 2003;15(1):74-77. doi:10.1176/jnp.15.1.74
Shen CC, Tsai SJ, Perng CL, Kuo BI, Yang AC. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology. 2013;81(17):1538-44. doi:10.1212/wnl.0b013e3182a956ad
Pjove V, Malkneht F. Nemotornye projavlenija prodromal'noj stadia bolezni Parkinsona. Bolezn' Parkinsona i rasstrojstva dvizhenija. M. 2014. (In Russ.).
Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for both impaired encoding and retrieval memory profiles in Parkinson's disease. Cogn Behav Neurol. 2004;17:195-200. doi:10.1177/1073191103258590
Gómez-Esteban JC, Tijero B, Somme J Ciordia R, Berganzo K, Rouco I, Bustos JL, Valle MA, Lezcano E, Zarranz JJ. Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease. J Neurol. 2011;258(3):494-499. doi:10.1007/s00415-010-5786-y
Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology. 2013;80:800-809. doi:10.1212/wnl.0b013e318285c0ed
Alonso A, Rodriguez LAG, Logroscino G, Hernan MA. Use of antidepressants and the risk of Parkinson's disease: a prospective study. J Neurol Neurosurg Psychiatry. 2009;80:671-675. doi:10.1136/jnnp.2008.152983
Chen JJ, Marsh L. Depression in Parkinson's disease: identification and management. Pharmacotherapy. 2013;33(9):972-83. doi:10.1002/phar.1314
Shatova AV. Narushenie kognitivnyh funkcij pri bolezni Parkinsona. M. 2009. (In Russ.).
Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G, Robinson RG. A validation study of depressive syndromes in Parkinson’s disease. Mov Disord. 2008;23(4):538-546. doi:10.1002/mds.21866
Marsh L, McDonald WM, Cummings J, Ravina B. NINDS/NIMH Work Group on Depression and Parkinson’s Disease. Provisional diagnostic criteria for depression in Parkinson’s disease: Report of an NINDS/NIMH Work Group. Mov Disord. 2006;21(2):148-158. doi:10.1002/mds.20723
Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol. 1990;3:3-9. doi:10.1177/089198879000300102
Erdal KJ. Depressive symptom patterns in patients with Parkinson’s disease and other older adults. J Clin Psychol. 2001;57(12):1559-1569. doi:10.1002/jclp.1118
Levin OS. Bolezn' Parkinsona kak nejropsihiatricheskoe zabolevanie. Nevrologija/Revmatologija. 2011;2:18-22. (In Russ.).
Ahmadeeva GN, Magzhanov RV. Trevozhno-depressivnye narushenija u pacientov s bolezn'ju Parkinsona v Respublike Bashkortostan. Ural'skij medicinskij zhurnal. 2015;2:44-48. (In Russ.).
Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatry. 2006;21(3):252-258. doi:10.1002/gps.1456
Lieberman A. Depression in Parkinson’s disease — a review. Acta Neurol Scand. 2006;113(1):1-8. doi:10.1111/j.1600-0404.2006.00536.x
Leentjens AFG. Depression in Parkinson’s disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol. 2004;17:120-126. doi:10.1177/0891988704267456
Assogna FF, Fagioli S, Cravello L, Meco G, Pierantozzi M, Stefani A, Imperiale F, Caltagirone C, Pontieri FE, Spalletta G. Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses. Neuropsychiatr Dis Treat. 2013;9:389-396. doi:10.2147/ndt.s40013
Nazem S, Siderowf AD, Duda JE, Brown GK, Ten Have T, Stern MB, Weintraub D. Suicidal and death ideation in Parkinson's disease. Mov Disord. 2008;10:1573-1579. doi:10.1002/mds.22130
Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis. 1990;178:27-31. doi:10.1097/00005053-199001000-00005
Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69:342-347. doi:10.1212/01.wnl.0000268695.63392.10
Nodel' MR, Jahno NN. Geterogennost' nervno-psihicheskihnarushenijpribolezniParkinsona. Bolezn' Parkinsona i rasstrojstva dvizhenija. M. 2014. (In Russ.).
Ahmadeeva GN, Tajupova GN, Bajtimerov AR, Magzhanov RV, Hidijatova IM, HusnutdinovaJeK. Izuchenie vozmozhnyh faktorov riska vozniknovenija trevozhno-depressivnyh narushenij u pacientov s bolezn'ju Parkinsona v Respublike Bashkortostan. Kazanskij Nevrologicheskij vestnik im. Behtereva. 2015;1:27-31. (In Russ.).
Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord. 2003;10(1):23-28. doi:10.1016/s1353-8020(03)00067-1
Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Depression and disability in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1996;8:20-25. doi:10.1176/jnp.8.1.20
Starkstein SE, Petracca G, Chemerinski E, Tesón A, Sabe L, Merello M, Leiguarda R. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord. 1998;13:29-33. doi:10.1002/mds.870130109
Aarsland D, Larsen JP, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56:595-601. doi:10.1001/archneur.56.5.595
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G, Ceravolo R, Cicarelli G, Gaglio RM, Giglia RM, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Dotto PD. The Priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Movement Disorders. 2009;24(11):1641-1649. doi:10.1002/mds.22643
Happe S, Lüdemann P, Berger K. FAQT study investigators. The association between disease severity and sleep-related problems in patients with Parkinson'sdisease. Neuropsychobiology. 2002;46(2):90-96. doi:10.1159/000065418
Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007;22:1077-1092. doi:10.1002/mds.21333
Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2003;16:178-183. doi:10.1177/0891988703256053
Richard I, Kurlan R. The under-recognition of depression in Parkinson’s disease. Neuropsychiatr Dis Treat. 2006;2(3):349-353. doi:10.2147/nedt.2006.2.3.349
Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2002;8(3):193-197. doi:10.1016/s1353-8020(01)00015-3
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26:42-80. doi.10.1002/mds.23884
Rektorová I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdlová Z, Fiedler J, Klajblová H, Kulist'ák P, Ressner P, Svátová J, Urbánek K, Velísková J. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol. 2005;12(1):9-15. doi:10.1111/j.1468-1331.2004.00966.x
Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573-580. doi:10.1016/s1474-4422(10)70106-x
Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886-892. doi:10.1212/01.wnl.0000336340.89821.b3
Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destée A, Bordet R, Defebvre L. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008;23(6):850-857. doi:10.1002/mds.21966
Kirsch-Darrow L, Fernandez HF, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology. 2006;67:33-38. doi:10.1212/01.wnl.0000230572.07791.22
Kummer A, Cardoso F, Teixeira AL. Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease. Mov Disord. 2008;23:1739-1743. doi:10.1002/mds.22221
Dissanayaka NNW, Sellbach A, Matheson S, O'Sullivan JD, Silburn PA, Byrne GJ, Marsh R, Mellick GD. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord. 2010;25:838-845. doi:10.1002/mds.22833
Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson’s disease: a cross-sectional study. Mov Disord. 2011;26(3):484-492. doi:10.1002/mds.23528
Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson’s disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34:465-470. doi:10.1016/0006-3223(93)90237-8
Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Anxiety disorders and depressive disorders preceding Parkinson's Disease: a case-control study. Mov Disord. 2000;15:669-677. doi:10.1002/1531-8257(200007)15:4669::aid-mds10113.0.co;2-5
Ardouin C, Lhomme E, Thobois S. Piribedil improves apathy, depression and anxiety in Parkinson’s disease. Mov Disord. 2009;24(suppl 1):233.
Litvinenko IV, Odinak MM, Shatova AV, Sologub OS. StrukturakognitivnyhnarushenijpriraznyhstadijahbolezniParkinsona. Vestnik Ros Voen-med akad. 2007;3:21-29. (InRuss.).
Fedorova NV, Mireckaja AV. Affektivnye rasstrojstva pri bolezni Parkinsona. Psihicheskie rasstrojstva v obshhej medicine. 2009;2:36-39. (In Russ.).
Chaudhuri K Ray, Rojo JM, Schapira AHV, Brooks DJ, Stocchi F, Odin P, Antonini A, Brown RJ, Martinez-Martin P. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS ONE. 2013;8:57221. doi:10.1371/journal.pone.0057221